Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. NPS had hit a rough patch in 2006. Over and over again, I have seen managers tolerate unacceptable behaviors because they believed the individuals’ technical expertise was vital.

Company 9

Company Pharmaceuticals Biotechnology Short-term 9

Harvard Business Review

FEBRUARY 22, 2013

Having observed management teams for decades as a mutual fund and portfolio manager, I have watched numerous companies vanish after a disastrous launch of a product or service. Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. What do you do next?

Productivity 8

Productivity Products Biotechnology IPO 8

Harvard Business Review

DECEMBER 30, 2011

That was the question Todd Pierce asked himself in 2006 after years of experimenting with the full menu of trainings, meetings, and competency models in his capacity as CIO of biotechnology giant Genentech. In other words, what if cultivating a successful inner life was front and center on the leadership agenda?

Development 17

Development Biotechnology CIO Short-term 17